The Technical AnalystExchange: HKSE Industry: Pharmaceuticals, Biotechnology & Life Sciences
WuXi Biologics (Cayman) Price, Forecast, Insider, Ratings, Fundamentals & Signals
-5.22% HKD13.80
America/New_York / 3 mai 2024 @ 02:25
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 58 778 mill |
| EPS: | 0.830 |
| P/E: | 16.63 |
| Earnings Date: | Mar 26, 2024 |
| SharesOutstanding: | 4 259.28 mill |
| Avg Daily Volume: | 57.74 mill |
| RATING 2024-05-02 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | n/a | n/a | n/a | |||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 1.00x |
| Company: PE 16.63 | sector: PE 16.62 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.33x |
| Company: PE 16.63 | industry: PE 50.72 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
HKD 12.69 - 14.91 ( +/- 8.02%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | HKD13.80 (-5.22% ) |
| Volume | 35.11 mill |
| Avg. Vol. | 57.74 mill |
| % of Avg. Vol | 60.80 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 2269.HK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
2269.HK
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.